The cannabinoid CB 1 (CB 1 ) and dopamine D 2 (D 2 ) receptors are coexpressed in the basal ganglia, an area of the brain involved in such processes as cognition, motor function, and emotional control. Several lines of evidence suggest that CB 1 and D 2 receptors may oligomerize, providing a unique pharmacology in vitro and in vivo. However, limited information exists on the regulation of CB 1 and D 2 receptor dimers. We used a novel technique, multicolor bimolecular fluorescence complementation (MBiFC) Increasing evidence suggests that G protein-coupled receptors (GPCRs) may function in receptor dimeric or higher order oligomeric complexes (for review, see Milligan, 2008) . One set of receptors that has received significant attention relevant to oligomerization is the CB 1 cannabinoid (CB 1 ) receptor and dopamine D 2 (D 2 ) receptor (for review, see Fuxe et al., 2008) . It is thought that the cannabinoid system negatively modulates dopamine circuits as activation of the CB 1 receptor leads to an attenuation of dopamine signaling (Laviolette and Grace, 2006) . The CB 1 receptor is widely expressed in the central nervous system, with great abundance in the basal ganglia (Herkenham et al., 1991) . CB 1 receptors are located on striatal GABAergic neurons (Herkenham et al., 1991) , and they are also found on dendrites in both the dorsal striatum and the nucleus accumbens (Pickel et al., 2006) . The D 2 receptor exists as two splice variants, D 2S (short) and D 2L (long). The D 2S variant is highly expressed on presynaptic dopaminergic neurons, whereas the D 2L variant is found postsynaptically on dopaminergic neurons throughout the striatum
Increasing evidence suggests that G protein-coupled receptors (GPCRs) may function in receptor dimeric or higher order oligomeric complexes (for review, see Milligan, 2008) . One set of receptors that has received significant attention relevant to oligomerization is the CB 1 cannabinoid (CB 1 ) receptor and dopamine D 2 (D 2 ) receptor (for review, see Fuxe et al., 2008) . It is thought that the cannabinoid system negatively modulates dopamine circuits as activation of the CB 1 receptor leads to an attenuation of dopamine signaling (Laviolette and Grace, 2006) . The CB 1 receptor is widely expressed in the central nervous system, with great abundance in the basal ganglia (Herkenham et al., 1991) . CB 1 receptors are located on striatal GABAergic neurons (Herkenham et al., 1991) , and they are also found on dendrites in both the dorsal striatum and the nucleus accumbens (Pickel et al., 2006) . The D 2 receptor exists as two splice variants, D 2S (short) and D 2L (long). The D 2S variant is highly expressed on presynaptic dopaminergic neurons, whereas the D 2L variant is found postsynaptically on dopaminergic neurons throughout the striatum (Khan et al., 1998; Usiello et al., 2000) .
1 These observations reveal that CB 1 and D 2L receptors have overlapping expression patterns in the striatum and also suggest that they are colocalized in neurons in the nucleus accumbens (see references within Kearn et al., 2005; Pickel et al., 2006) .
It has been reported that CB 1 and D 2 receptors oligomerize, providing unique pharmacology in vitro and in vivo (Glass and Felder, 1997; Jarrahian et al., 2004; Kearn et al., 2005; Marcellino et al., 2008) . For example, it was demonstrated in primary rat striatal neurons that concurrent activation of G␣ i/o -coupled CB 1 and D 2 receptors resulted in stimulation of cAMP accumulation (Glass and Felder, 1997) . Subsequent experiments using recombinant CB 1 and D 2L receptors suggested that D 2L receptor activation promoted a switch in CB 1 receptor coupling from G␣ i/o to G␣ s (Glass and Felder, 1997) . One proposed mechanism for D 2 receptor modulation of CB 1 -G protein coupling may involve receptor oligomerization. This hypothesis was examined by demonstrating a physical interaction between CB 1 and D 2L receptors using coimmunoprecipitation (Kearn et al., 2005) . The same investigators also revealed that the CB 1 -D 2L receptor complex can be dynamically modulated by receptor agonists. More recent studies have examined CB 1 -D 2L heteromers using FRET techniques . Using human embryonic kidney cells transiently transfected with fluorescently tagged CB 1 and D 2L receptors, a FRET interaction was detected. However, no significant changes in the FRET signal were detected after short-term exposure to CB 1 or D 2L receptor agonists . The ability of CB 1 and D 2L receptors to interact is consistent with suggestion of a CB 1 -D 2L heterodimer. Additional behavior and biochemical data support further the physiological relevance of CB 1 and D 2 receptors heterodimers . However, limited information exists on the cellular localization and regulation of CB 1 -D 2L receptor heterodimers. Despite the therapeutic potential of drugs targeting these receptors, the effect of persistent receptor activation on the dynamics of receptor oligomerization has not been explored.
The most common techniques currently being used to study the physical association of GPCRs include coimmunoprecipitation and traditional resonance energy transfer (FRET and BRET) techniques (Vidi and Watts, 2009) . These techniques are typically limited to the study of a single protein-protein complex. In addition, coimmunoprecipitation does not allow for detection of an interacting protein complex within a living cell. To gain further insight into GPCR dimerization in live cells, we recently established the use of multicolor bimolecular fluorescence complementation (MBiFC) (Hu et al., 2002; Shyu et al., 2006) as a tool to investigate GPCR homo-and heteromer oligomerization (Vidi et al., 2008a,b) . MBiFC allows for the detection of two separate protein-protein complexes in living cells by visualizing the fluorescence complementation of two distinct spectral variants of green fluorescent protein (Hu and Kerppola, 2003) . Moreover, this technique can be used to measure the relative amounts of homodimer versus heterodimer formation in a cell region-specific manner (Vidi et al., 2008b) .
The present study uses MBiFC to examine CB 1 -D 2L heterodimers and D 2L -D 2L homodimers in Cath. a differentiated (CAD) cells. CAD cells are a neuronal cell model that express GAP-43, synaptotagmin, and synaptosome-associated protein of 25 kDa and upon differentiation, form neurite-like processes (Qi et al., 1997) . The present results provide additional evidence for the existence of CB 1 and D 2L receptor oligomers. We also revealed that persistent agonist (i.e., dopaminergic or cannabinergic) treatment favors the formation of the CB 1 -D 2L heterodimer relative to the formation of the D 2L -D 2L homodimer. The D 2 agonist-mediated effects were accompanied by an increase in D 2L receptor expression, whereas the CB 1 agonist-mediated changes in heterodimer formation appeared to involve primarily CB 1 receptor activation. These results provide further insight into the dynamic nature of CB 1 -D 2L oligomerization. Expression Vectors. Full-length human CB 1 and D 2L cDNAs were amplified by polymerase chain reaction (PCR) using oligonucleotides with EcoRI, XbaI, or XhoI restriction sites and omitting the stop codons. The PCR products were digested with either EcoRI/XbaI or EcoRI/XhoI and ligated into the corresponding pBiFC vectors. These expression vectors contain nonfluorescent fragments of the N and C termini of the enhanced yellow fluorescent protein (Venus) and the enhanced cyan fluorescent protein (Cerulean). The N-terminal fragments (VN or CN) include residues 1 to 172, whereas the C-terminal fragment of Cerulean (CC) includes residues 155 to 238. This cloning strategy places the fragment on the C terminus of the receptors. In addition, the CB 1 and D 2L receptor PCR products were digested with either EcoRI/XbaI or EcoRI/XhoI and ligated into expression vectors containing the full-length Venus or Cerulean proteins resulting in the CB 1 and D 2L receptors tagged at the C terminus with either Venus or Cerulean. The CB 1 receptor mutant (CB 1 T210I) was generated using the QuikChange kit according to the supplier's protocol (Stratagene, La Jolla, CA) in pcDNA3-CB 1 and then subcloned into the pBiFC vectors using EcoRI and XbaI restriction enzyme sites. All constructs were verified by DNA sequencing.
Materials and Methods

Materials
Cell Culture and Transient Transfections. CAD cells were maintained as described previously (Vortherms and Watts, 2004) . For microscopic evaluation of BiFC, CAD cells were grown to approximately 70% confluence in four-well LabTek chambered coverslips (Nalge Nunc International, Rochester, NY). Cells were transfected with 1 l of Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendations. In MBiFC experiments, CB 1 -VN (500 ng), D 2L -CC (300 ng), and D 2L -CN (300 ng) were transiently cotrans-fected with 20 ng of either mCherry-Mem, YFP-Endo, YFP-ER, or YFP-Golgi depending on the experiment. Twenty-four hours after transfection, the growth media and transfection reagent were replaced with 400 l of warm phosphate-buffered saline (PBS), and images were taken using a charge-coupled device camera mounted on a TE2000-U inverted fluorescence microscope (Nikon, Melville, NY) equipped with a 100-W mercury lamp and band-pass filters (Chroma Technology Corp., Rockingham, VT) for Venus (excitation at 500/20 nm; emission at 535/30 nm), Cerulean (excitation, 430/25 nm; emission, 470/30 nm), or mCherry (Texas Red, excitation, 572/23 nm; emission, 625/25 nm). Fluorescent images were acquired using MetaMorph software (Molecular Devices, Sunnyvale, CA). For MBiFC experiments investigating the effects of receptor ligands on receptor dimer population, the cells were transfected as described above and 4 h after transfection, the appropriate drug treatment was added to the growth medium for an additional 20 h before image acquisition.
Quantitative Image Analysis. Quantification of fluorescent signals was performed as described previously using ImageJ software (http://rsb.info.nih.gov/ij/; Hu et al., 2002; Supplemental Fig. 1) . In each experiment, approximately 40 to 50 individual cells were quantified. Ten microscopic fields at 60ϫ magnification were acquired as stacks of images from the YFP, CFP, and Texas Red channels corresponding to the fluorescent signals from Venus, Cerulean, and mCherry proteins, respectively. Background fluorescence intensity was measured in each channel in an area devoid of cells and subtracted from the fluorescent signals. The signals corrected for background fluorescence were then scaled to a factor equal to that of the inverse of the exposure time for each pixel intensity measurement. The images of the mCherry-Mem membrane marker signal were used to select cells for image analysis and to normalize BiFC signals (Supplemental Fig. 1 ). Cellular analysis of BiFC signals was performed in two parts. First, the fluorescent signal intensity maximum at the membrane was determined by drawing a perpendicular line through the membrane using the mCherry-Mem image. The maximum signal intensity was determined in all three channels, YFP, CFP, and Texas Red to estimate the BiFC signals at the membrane. The BiFC signal intensity in the intracellular space was determined by outlining the intracellular compartment (excluding the plasma membrane) and determining the average pixel intensity in all three channels, YFP, CFP, and Texas Red, to estimate the intracellular BiFC signals. Cells with saturated signals as well as cells with signals that were 1.2 times lower than background were not used for quantification. BiFC experiments assessing bleed-through/overflow of Cerulean or Venus in the opposite channels (i.e., YFP or CFP) revealed minimal cross-talk. Specifically, complemented Cerulean contributed less than 2% of the YFP signal and complemented Venus contributed less than 3% of the CFP signal (data not shown). Venus/ Cerulean fluorescence ratios exhibit a non-Gaussian distribution; therefore, median values were calculated and averaged between experiments.
Cyclic AMP Accumulation Assays. CAD cells were grown to 70% confluence in 24-well plates and were transiently transfected as described previously (Vidi et al., 2008a) . CAD cells were either transfected with 300 ng/well D 2L constructs or 500 ng/well CB 1 constructs. All drugs were diluted in Earle's balanced salt solution assay buffer (Earle's balanced salt solution containing 2% bovine calf serum, 0.025% ascorbic acid, and 15 mM HEPES, pH 7.4) and added to the cells on ice. Determination of cAMP accumulation was performed by incubating the transfected CAD cells with forskolin (10 M) in the absence and presence of either CP55,940 (10 M) or quinpirole (10 M) for 15 min at 37°C. All assays were performed in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (500 M) and terminated with ice-cold 3% trichloroacetic acid. Quantification of cAMP accumulation was determined using a competitive binding assay as described previously (Vortherms and Watts, 2004) .
Radioligand Binding Assays. Single point radioligand binding assays were used to estimate CB 1 and D 2L receptor densities after drug treatments as described previously (Vidi et al., 2008a) . CAD cells were plated in a 12-well plate and were grown to 70% confluence before being transiently transfected with CB 1 -VN, D 2L -CN, and D 2L -CC using 2 l/well of Lipofectamine 2000. Four hours after transfection, the appropriate drug treatment was added in triplicate to the growth medium and transfection reagent. The cells were incubated for an additional 20 h before single point radioligand binding assays. Cells were washed three times with 500 l of receptor binding buffer (50 mM Tris and 4 mM MgCl 2 , pH 7.4). The cells were lysed with 500 l of ice-cold lysis buffer (1 mM HEPES and 2 mM EDTA, pH 7.4) for 10 min on ice. The cells were removed from each well by trituration, and crude cell membranes were collected by centrifugation (30,000g for 15 min at 4°C). Membrane pellets were resuspended by mechanical homogenization in 1 ml of receptor binding buffer. For CB 1 receptor binding, the addition of 0.5% bovine serum albumin to the receptor binding buffer was used to decrease nonspecific binding. Crude cell membranes (approximately 30 g in 150 l) were added in duplicate to the assay tubes to determine both nonspecific and total binding. For CB 1 binding, nonspecific binding was defined by 10 M nonradioactive SR141716A (essentially identical levels of nonspecific binding were obtained using 10 M AM281; data not shown). All tubes contained a nearsaturating amount of [ 3 H]SR141716A (50 l; final concentration, ϳ5.0 nM) in a total volume of 500 l. Likewise, for D 2 binding, nonspecific binding was defined with 5 M (ϩ)-butaclamol, with all reaction conditions containing a near-saturating amount of [ 3 H]spiperone (50 l; final concentration, ϳ1.5 nM) in a total volume of 500 l. The reaction was terminated by filtration onto FB glass fiber plates with ice-cold wash buffer (10 mM Tris and 0.9% NaCl) using a cell harvester (FilterMate; PerkinElmer Life and Analytical Sciences). Radioactivity was determined a TopCount scintillation counter (PerkinElmer Life and Analytical Sciences). Specific binding was determined as the difference between the average of the nonspecific and total binding conditions. The specific binding amount was normalized to the amount of protein using the bicinchoninic acid protein assay (Pierce Chemical, Rockford, IL) following the supplier's protocol. Under the transfection conditions used to explore the effects of drug treatments on BiFC, the following estimated Fluorescence Energy Transfer. CAD cells were grown to 70% confluence in 12-well plates before transfection. Cells were transiently transfected with three general conditions depending on the receptor dimer species to be studied including: cells only expressing the FRET donor (Cerulean), cells only expressing the FRET acceptor (Venus), and cells expressing both the donor and acceptor. To normalize for protein expression in cells only expressing either the donor or acceptor, the total amount of DNA transfected was normalized with the untagged receptor. In each FRET assay, 750 ng/well of the donor (CB 1 -Cerulean or D 2L -Cerulean) and 750 ng/well of the acceptor (CB 1 -Venus or D 2L -Venus) were transiently transfected either alone or in combination 24 h before the experiment. Cells were washed with 500 l of warm PBS and resuspended in 300 l of warm PBS. Protein concentration was determined on the cell suspension using the bicinchoninic acid assay method (Pierce Chemical) and normalized to 200 ng/l with PBS. CAD cells suspensions (40 g) were transferred into a 96-well black plate (Nalge Nunc International), and fluorescence measurements were evaluated on the FUSION plate reader (PerkinElmer Life and Analytical Sciences). Determination of FRET signals was performed as described previously (Vidi et al., 2008b) . In brief, FRET signals were measured using the sensitized acceptor method. Mock-transfected cells were used for background fluorescence. For each sample, Cerulean (C) and Venus (V) was measured using 430/25 nm and 500/20 nm excitation and 470/30 nm and 535/30 nm emission filters. FRET signals (F) were measured using excitation at 430/25 nm and emission at 535/30 nm. Bleed-through coefficients were calculated for the acceptor (a ϭ F/V) and for the donor (d ϭ F/C)
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Przybyla and Watts at ASPET Journals on July 10, 2017 jpet.aspetjournals.org in cells only expressing either Cerulean (donor) or Venus (acceptor) fusion proteins. The FRET signals were corrected (cFRET) for acceptor and donor bleed-through using the equation cFRET ϭ F Ϫ aV Ϫ dC. The signals were then normalized to donor (C) and acceptor (Y) intensities as follows: nFRET ϭ cFRET/͌C ϫ V.
Data and Statistical Analysis. Data and statistical analyses were performed using Prism (GraphPad Software Inc., San Diego, CA). A p value Ͻ0.05 was considered significant.
Results
Functional cAMP accumulation assays were performed to verify the signaling properties of the BiFC-tagged CB 1 and D 2L receptors (Fig. 1) . Because CB 1 and D 2L receptors couple to inhibitory G proteins (i.e., G␣ i/o ), agonist-induced inhibition of forskolin-stimulated cAMP accumulation was used to evaluate receptor function. The BiFC-tagged D 2L receptors D 2L -CN and D 2L -CC were functional after stimulation with the D 2 agonist quinpirole (10 M), revealing approximately 60% inhibition of forskolin-stimulated cAMP accumulation (Fig. 1A) . Additional experiments confirming the functionality of the BiFC-tagged CB 1 receptors, CB 1 -VN and CB 1 -CC, were performed. Both constructs were functional after stimulation with the CB 1 receptor agonist CP55,940 (10 M), yielding more than 35% inhibition of forskolin-stimulated cAMP accumulation (Fig. 1B) . A modest but insignificant degree (approximately 10%) of inhibition was also observed in vector-transfected CAD cells. Receptor signaling in cells coexpressing the wild-type or BiFC-tagged receptors was also examined (Fig. 1, A MBiFC is novel technique that allows for the simultaneous study of two receptor dimer species within living cells ( Fig. 2A ; Vidi and Watts, 2009) 2B ). The formation of CB 1 -D 2L heterodimers supports previous studies demonstrating interactions between CB 1 and D 2L receptors (Kearn et al., 2005; Marcellino et al., 2008) .
One goal of the present study was to assess the dynamic nature of the CB 1 -D 2L heterodimer in response to persistent drug treatment. This required the establishment of MBiFC as described previously for A 2A adenosine and D 2L dopamine receptors (Vidi et al., 2008a) . Using this approach, CAD cells were transiently transfected with CB 1 -VN, D 2L -CC, and D 2L -CN to simultaneously visualize CB 1 -D 2L and D 2L -D 2L receptor dimers using fluorescence microscopy ( Fig. 2A) . The presence of a Venus signal is indicative of the CB 1 -D 2L heterodimer, whereas a Cerulean signal corresponds to the D 2L -D 2L homodimer (Fig. 2B) . CAD cells transfected with CB 1 -VN, D 2L -CC, and D 2L -CN expressed both Venus and Cerulean signals consistent with the coexistence of CB 1 -D 2L heterodimers and D 2L -D 2L homodimers (Fig. 2B) . Fluorescent signals corresponding to the receptor dimers showed a similar pattern of distribution and were found at the plasma membrane as well as intracellularly. For comparison with the BiFC signals, the localization patterns of CB 1 -Venus and D 2L -Cerulean were evaluated after coexpression (Fig. 2C) . The CB 1 -Venus signal showed significant intracellular localization, whereas the D 2L -Cerulean displayed localization at both the plasma membrane and intracellular compartments. Moderate overlap between the CB 1 and D 2L signals was also observed. For additional comparison, the individual expression patterns of CB 1 -Venus and D 2L -Venus were examined (Fig.  2D) . When expressed alone, the CB 1 -Venus signal was primarily localized intracellularly demonstrated by the lack of overlap with the membrane marker (merge panel). Conversely, the D 2L -Venus expression was found primarily at the membrane and extensive overlap with the membrane marker was displayed (Fig. 2D) .
We also attempted to perform MBiFC experiments to simultaneously examine D 2L -CB 1 and CB 1 -CB 1 dimers. Unfortunately, the fluorescent signal of the CB 1 -CB 1 dimer under MBiFC conditions was too low to reliably measure, restricting our MBiFC experiments to CB 1 -D 2L and D 2L -D 2L receptor dimers. The lack of a CB 1 -CB 1 dimer BiFC signal may reflect one of the disadvantages of BiFC. Specifically, the intensity of the fluorescence complementation signal is considerably weaker (2.5-5.5-fold) than the signal from the corresponding full-length fluorescent protein under similar transfection conditions (Vidi and Watts, 2009) .
One advantage of BiFC is the ability to investigate the localization of the receptor dimers using epifluorescence. With the use of fluorescently tagged intracellular makers, the patterns of intracellular expression of the CB 1 -D 2L and D 2L -D 2L receptor dimers were investigated using fluorescent microscopy (Fig. 3) . CAD cells were transiently transfected with BiFC constructs that reconstitute Cerulean to either express the CB 1 -D 2L heterodimer (CB 1 -CN ϩ D 2L -CC) or the D 2L -D 2L homodimer (D 2L -CN ϩ D 2L -CC). In addition, these cells were transfected with the indicated YFP-tagged intracellular marker proteins (YFP-Endo, YFP-ER, or YFP-Golgi; Fig. 3 ). The endosome marker (YFP-Endo) is a fusion protein with RhoB, a known endosomal protein fused to YFP. The ER marker (YFP-ER) consists of YFP fused to the ER targeting sequence of calreticulin and the KEDL ER retrieval sequence. The Golgi marker (YFP-Golgi) is a YFP fusion protein with residues 1 to 81 of the ␤1,4-galactosyltransferase protein. Overall, both receptor dimers, D 2L -D 2L and CB 1 -D 2L displayed moderate to extensive overlap with endosome and ER structures (Fig. 3, A and B) . However, CB 1 -D 2L and D 2L -D 2L receptor dimers demonstrated minimal to no overlap with the Golgi apparatus. These expression patterns are consistent with receptor dimer assembly at the ER (HerrickDavis et al., 1997) and proper trafficking into endosomes (Leterrier et al., 2004) . However, the additional possibility that receptors dimerize at the plasma membrane cannot be excluded in the absence of additional studies.
The results demonstrating MBiFC in neuronal cells were further validated by examining dimerization of these receptors jpet.aspetjournals.org using FRET, which has been used previously to investigate interactions of CB 1 and D 2L receptors . CAD cells were transiently transfected with either CB 1 -Venus ϩ CB 1 -Cerulean, CB 1 -Venus ϩ D 2L -Cerulean, or D 2L -Venus ϩ D 2L -Cerulean (Fig. 4) . A significant FRET signal was detected with all three receptor pairs compared with the mix control sample in which suspensions of cells only expressing the donor or acceptor was mixed in the FRET sample plate. These results provide further confirmation of our BiFC studies, supporting the hypothesis that CB 1 and D 2 form both homo-and heteromeric receptor oligomers in a neuronal-like cell model.
Using MBiFC and FRET techniques, we have provided evidence that CB 1 and D 2 receptors participate in receptor dimer complexes. We next sought to investigate the effects of persistent ligand treatment on the formation of CB 1 and D 2L heterodimer and D 2L homodimers using MBiFC as a tool to monitor changes in relative receptor dimer population. CAD cells were transiently transfected with CB 1 -VN, D 2L -CC, and D 2L -CN, and the presence of the CB 1 -D 2L heterodimer (Venus) and D 2L -D 2L homodimer (Cerulean) was simultaneously measured. The fluorescent intensity ratio of Venus to Cerulean in both the plasma membrane and intracellular compartments was determined after drug treatment. Under the conditions used, an increase in the Venus-to-Cerulean ratio would be indicative of an increase in the formation of the CB 1 -D 2L receptor dimer relative to the D 2L -D 2L receptor dimer compared with vehicle-treated cells.
Our previous work with D 2 and A 2A receptor ligands suggested that a 20-h drug treatment provided a robust BiFC signal in which drug-induced changes in A 2A -D 2L , D 2L -D 2L , and A 2A -A 2A dimers could be observed (Vidi et al., 2008a) . In the present study, we completed MBiFC time course experiments with the CB 1 receptor ligand CP55,940 to verify that a similar treatment duration produced robust responses in the absence of a ceiling effect. The results of the time course study revealed that CP55,940 treatments shorter than 10 h (i.e., 5 h) had very low fluorescent signals and did not allow us to quantify an adequate number of cells for analysis (data not shown). However, robust YFP and CFP signals were evident after 10 h and the drug effects were time-dependent showing the greatest response at 30 h (Fig. 5) . The time course study also suggested that the 20-h time point is on the dynamic portion of the temporal scale potentially allowing us to observe ratiometric changes in both directions as shown previously (Vidi et al., 2008a) . Examination of the overall YFP and CFP intensities at 20 h indicated that the CP55,940-induced increase in the YFP/ CFP ratio reflected a combined increase in the YFP signal (CB 1 -D 2L ) and a decrease in the CFP signal (D 2L -D 2L ) compared with vehicle-treated cells. Specifically, the membrane showed an 11% increase in YFP and a 27% decrease in CFP intensity. Intracellularly, there was 33% increase in the YFP signal and a 15% decrease in the CFP signal (n ϭ 4).
Drug-induced changes in the relative receptor dimer population were measured after treatment (20 h) with either D 2 (Fig. 6A) or CB 1 (Fig. 6B ) receptor ligands. Persistent activation of the D 2L receptor with quinpirole (10 M) resulted in a significant increase in the Venus-toCerulean ratio consistent with an increase in CB 1 -D 2L heterodimers relative to D 2L -D 2L homodimers. However, this effect was only significant in the intracellular compartment. The effect of quinpirole was prevented by coapplication of the selective D 2 receptor antagonist sulpiride (1 M). Treatment with sulpiride alone or in combination with quinpirole resulted in a significant decrease in the Venus to Cerulean ratio in both the membrane and intracellular compartments. Because the observed alterations in receptor dimer population may involve changes in re- jpet.aspetjournals.org ceptor expression, single point radioligand binding experiments were used to estimate relative receptor densities after drug treatment. The results of these studies revealed that persistent treatment with quinpirole (10 M), sulpiride (1 M), or quinpirole ϩ sulpiride significantly increased D 2L receptor density (118 Ϯ 6, 149 Ϯ 17, or 129 Ϯ 9%; n ϭ 5) compared with vehicle treatment (100%). These ligand-induced increases in D 2L receptor expression are consistent with our previous report (Vidi et al., 2008a) and work from others (Sibley and Neve, 1997) . No significant changes in CB 1 receptor density were observed upon persistent treatment with either of the D 2 receptor ligands alone or the combination (data not shown).
MBiFC experiments were also performed using CB 1 ligands. Persistent treatment with the CB 1 receptor agonist CP55,940 (10 M) led to a significant increase in the Venus-to-Cerulean ratio in both the plasma membrane and the intracellular regions compared with vehicletreated cells (Fig. 6B) . The addition of the CB 1 receptor antagonist AM281 (10 M) attenuated the CP55,940-induced increase in the Venus-to-Cerulean ratio. Dose-response experiments revealed that the average EC 50 values for CP55,940 increasing the YFP/CFP ratio were 320 and 210 nM for membrane and intracellular signals, respectively (Fig. 7) . Subsequent single point radioligand binding experiments revealed that 20-h treatment with CP55,940 had no effect on CB 1 receptor density (106 Ϯ 12%; n ϭ 5); however, a modest decrease in D 2L receptor density (82 Ϯ 3%; n ϭ 5) was observed.
The observations described above suggest that persistent activation of the CB 1 receptor favors the formation of CB 1 -D 2L heterodimers without alterations in CB 1 receptor expression. To investigate further the role of persistent activation on receptor dimerization, a constitutively active CB 1 receptor mutant was constructed for use in the MBiFC experiments. Threonine 210 of the CB 1 receptor was mutated to an isoleucine (CB 1 T210I) to create a constitutively active receptor (D'Antona et al., 2006) . The presence of an isoleucine at amino acid 210 disrupts the salt bridge in the DRY motif mimicking receptor activation, leading to enhanced agonist affinity and increased intracellular localization (D'Antona et al., 2006) . We examined and compared the relative receptor heterodimer (CB 1 -D 2L ) and homodimer (D 2L -D 2L ) populations in cells expressing either the wild-type (CB 1 wt) or the constitutively active CB 1 receptor (CB 1 T210I) using MBiFC (Fig. 8) . The Venus-(CB 1 -D 2L ) to-Cerulean (D 2L -D 2L ) ratios at the plasma membrane were similar in cells expressing the wild-type or constitutively active CB 1 (Fig. 8A) . In contrast, expression of CB 1 T210I resulted in a significant increase in the intracellular Venus-to-Cerulean ratio compared with the wild type CB 1 (Fig. 8A) . The intracellular-to-membrane ratio of the Venus signal (i.e., CB 1 wt-D 2L or T210I-D 2L dimer) in cells expressing the CB 1 T210I mutant was also significantly increased (approximately 150%) compared with cells expressing CB 1 wt (Fig. 8, A 
Discussion
Evidence for the existence and functional significance of CB 1 and D 2L heterodimers has continued to evolve over the jpet.aspetjournals.org past 10 to 15 years. However, investigations examining the regulation of these heterodimers and their homodimer counterparts are just beginning as new technological advances for studying protein-protein interactions are developed (Vidi and Watts, 2009 ). In the present study, we have applied MBiFC as a novel technique to study the dimerization of CB 1 and D 2L receptors, and we reveal for the first time the localization patterns of these receptor heterodimers in a neuronal cell model.
Early studies of CB 1 and D 2L function were central to the development of the concept of CB 1 -D 2L heterodimer (for review, see . Several studies suggest that the CB 1 -D 2L dimer possesses stimulatory properties toward adenylyl cyclase via the CB 1 receptor engaged in the heterodimer (Glass and Felder, 1997; Jarrahian et al., 2004; Kearn et al., 2005) . However, conflicting conclusions from studies examining the regulation of CB 1 and D 2L receptor dimerization remain. One potential mechanism for regulating the CB 1 -D 2 dimer is based on observations that the physical association of CB 1 and D 2L increases in the presence of acute coactivation of both receptors (Kearn et al., 2005) . Activation of either CB 1 or D 2L receptor individually did not significantly increase the physical association, suggesting that coactivation of both receptors is necessary for enhanced receptor dimerization. It was also reported that expression (and not activation) of the D 2L receptor was sufficient to induce a switch in CB 1 -G protein coupling to a stimulatory pathway, however, measurements of the CB 1 -D 2L receptor dimer were not performed (Jarrahian et al., 2004) . In addition, another study reported a lack of agonist-mediated increase in the FRET interaction between CB 1 and D 2 receptors under conditions of both single and concurrent receptor activation . The lack of consistency between the reports described above may reflect differences in the choice of receptor ligands, the model systems, technical approaches, or the complex pharmacology of the CB 1 -D 2 dimer.
In the present study, we used MBiFC to show that persistent activation of either the CB 1 or D 2L receptor leads to the formation of more CB 1 -D 2L heterodimers relative to the D 2L -D 2L homodimers. There are several differences between our study of CB 1 -D 2L interactions and the previous work described above (e.g., cell type, methods to measure receptors, drug treatment); however, the drug treatment conditions and technology used to assess the receptor dimers probably have significant influence. Each of the drug treatments reported here represents an extended drug exposure (i.e., 10 -30 h). Drugs were added 4 h after transfection and were present during the time of ongoing receptor biosynthesis and subsequent oligomerization. Therefore, the dimers observed in our studies probably involve mechanisms not reflected in shorter drug treatments or acute studies (Kearn et al., 2005; Marcellino et al., 2008) . The present study used BiFC technology, which differs from FRET in that the complementation of fluorescent signal is essentially irreversible (Vidi and Watts, 2009 ). This property of MBiFC allows investigators to "capture" and subsequently measure drug-induced changes in receptor dimers over an extended period in which a sufficient signal can be collected.
Persistent D 2 agonist treatment with quinpirole favored the formation of CB 1 -D 2L heterodimers versus D 2L -D 2L homodimers. This effect was accompanied by an increase in D 2L receptor expression and was prevented by the D 2 antagonist sulpiride. The increase in D 2L receptor expression may suggest a pharmacological chaperone effect on receptor dimer formation where D 2 ligands stabilize the receptor, somehow promoting CB 1 -D 2L receptor interactions (Vidi et al., 2008b) . However, treatment with the D 2 antagonist sulpiride also (Vidi et al., 2008b) . In addition to ligands, these dimerization patterns also appear to be influenced by the receptors under investigation. In a previous study of D 2L and A 2A receptor dimerization, quinpirole increased D 2L -D 2L homodimers relative to A 2A -D 2L heterodimers (Vidi et al., 2008b) . The potential scenario gets increasingly complicated when considering a recent BiFC-BRET study providing evidence for a CB 1 -D 2 -A 2A receptor oligomer . Linking the observations described above and the present results suggests a scenario where striatal neurons expressing D 2L , A 2A , and CB 1 receptors would be subject to a very complicated receptor regulation scheme. For example, persistent D 2 agonist treatment would increase overall D 2L receptor expression levels and perhaps promote the following pattern of receptor oligomers
The potential physiological and functional significance of these ligand-induced changes in heterodimers are intriguing and await biochemical and behavioral analysis . In addition to in vivo studies, new molecular tools to study these complex systems are becoming increasingly available as methods to study interactions of higher ordered GPCR oligomers (e.g., trimers and tetramers) such as BiLC-FRET, BiFC-FRET, and BiFC-BRET are developed (Vidi and Watts, 2009) .
The ability of quinpirole to alter the formation of receptor oligomers involving D 2L receptors may provide insight into the disease states associated with persistent D 2 receptor activation, as in the treatment of Parkinson's disease with L-DOPA and D 2 dopamine receptor agonists (Hurley and Jenner, 2006) . For example, persistent quinpirole treatment increases A 2A -A 2A homodimer formation and A 2A signaling (Vortherms and Watts, 2004; Vidi et al., 2008a) . These observations may provide a molecular explanation for the beneficial clinical effects of A 2A antagonists in treating L-DOPAinduced dyskinesias (Morelli et al., 2007; Fuxe et al., 2008) . The current results suggest that persistent treatment with D 2 receptor agonist drugs may promote the formation of CB 1 -D 2L heterodimers. The increase in CB 1 -D 2L dimer formation may allow the CB 1 receptor to have enhanced antagonistic effects over the D 2 receptor signaling . This scenario would provide for increased CB 1 signaling after a dopamine receptor-dependent increase in endocannabinoid release (Giuffrida et al., 1999; Piomelli, 2003) . In addition, evidence linking the CB 1 -D 2L heterodimer to a stimulatory pathway (Glass and Felder, 1997; Kearn et al., 2005) (Cao et al., 2007) . Another study revealed that rimonabant, a CB 1 receptor inverse agonist, had beneficial effects in managing L-DOPA-induced dyskinesias (van der Stelt et al., 2005) .
Similar to the D 2L receptors, the precise mechanism by which persistent activation of the CB 1 receptor favors the formation of CB 1 -D 2L heterodimers relative to D 2L -D 2L homodimers remains largely unknown. Our observations suggest that the formation of the heterodimer is mediated by receptor activation and not alterations in CB 1 receptor expression. It is possible that the activated conformational state of the CB 1 receptor possesses enhanced affinity for the D 2L receptor and that persistent activation promotes CB 1 -D 2L heterodimerization. This hypothesis is supported by the report that the CB 1 receptor increases the association with the D 2L receptor in a dose-dependent manner (Kearn et al., 2005) . Furthermore, the present study demonstrated that expression of a constitutively active CB 1 mutant, CB 1 T210I, promoted more CB 1 -D 2L heterodimerization. Although the identification of a molecular mechanism awaits further study, it is tempting to consider that CB 1 -D 2L interactions will represent a new CB 1 receptor signaling pathway that may be subject to functional selectivity (Glass and Northup, 1999; Mukhopadhyay and Howlett, 2005; Urban et al., 2007) .
The physiological significance and functional consequences of CB 1 receptor-induced CB 1 -D 2L dimers may have implications in the use of clinical cannabinoids to treat chronic pain as well as chronic marijuana use. Such conditions would involve persistent CB 1 receptor activation, providing an impetus to understand the molecular adaptations that occur in the nervous system (Cooper and Haney, 2008) . Although we were able to study drug-induced changes of the CB 1 -D 2L and D 2L -D 2L receptor dimers, a low BiFC signal between CB 1 receptors prevented us from examining the ratios of CB 1 -CB 1 homodimers to CB 1 -D 2L heterodimers. In the absence of CB 1 -CB 1 studies, the CP55,940-induced increase in the CB 1 -D 2L heterodimer may reflect a relative decrease in D 2L -D 2L homodimers and perhaps D 2L function. Consistent with this possibility we observed a modest CP55,940-induced decrease (approximately 15-25%) in D 2L receptor expression and D 2L -D 2L homodimers. These observations may suggest that persistent CB 1 receptor activation and subsequent CB 1 -D 2L heterodimer formation could reduce D 2L receptor expression. In partial support of this hypothesis, it has been shown in rats and humans that chronic prenatal exposure to marijuana decreases the expression of dopamine D 2 receptors in the brain (Walters and Carr, 1986; Wang et al., 2004) .
In the present report, we have visualized simultaneously the localization patterns of CB 1 -D 2L heterodimers and D 2L -D 2L homodimers in living cells and provided evidence for agonist-regulated effects on receptor dimerization patterns. Recent studies propose that an increasing number of GPCRs may participate in higher order receptor oligomers or "receptor mosaics" and that these structures may mediate many signaling events (for review, see Fuxe et al., 2008) . The present work and other recent studies are consistent with this concept Navarro et al., 2008) . We anticipate the continued development of new technologies will allow investigators to examine these receptor mosaics in greater detail. Finally, the use of MBiFC provides a new tool to study drug-induced changes in receptor oligomerization and may offer an important asset relevant to the future of drug discovery in the area of receptor heterodimers. 
